Work

The Collagen–LAIR1 axis as an emerging immune checkpoint in non-small cell lung cancer

Year: 2026
Type: article
Abstract: Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) blockade has transformed the treatment of non-small cell lung cancer (NSCLC), yet stromal immune exclusion and adaptive suppression limit durable responses. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1; CD305) is an inhibitory collagen-binding receptor that links the extracellular matrix to immune signaling. This Mini Review examines the biological basis, cellular context, and therapeutic implications of the collagen–LAIR1 checkpoint in NSCLC. Experimental lung cancer studies show that increased collagen deposition can accompany CD8+ T-cell dysfunction and resistance to PD-1/PD-L1 blockade, while LAIR1 antagonism or ligand competition can restore antitumor activity in selected models. LAIR1 also influences myeloid cells, although its functions are context dependent: suppressive tumor-associated macrophage programs coexist with evidence that LAIR1 supports normal monocyte and lung macrophage homeostasis. Recent NSCLC studies additionally demonstrate collagen-based physical barriers and fibroblast-mediated immune exclusion that should not automatically be attributed to LAIR1 signaling. We critically evaluate anti-LAIR1 antibodies, LAIR2-based decoy molecules, extracellular-matrix interventions, and combinations with conventional checkpoint inhibitors. Finally, we propose spatially resolved, cell-type-specific biomarker strategies to distinguish receptor-dependent inhibition from collagen architecture and to guide prospective clinical validation. The collagen–LAIR1 axis is a biologically compelling, but clinically unvalidated, immunotherapy target in NSCLC.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7235145802
FWCI:
Cites: 36
Cited by:
Related to: 10